SecBot SecBot
Insider Cluster (3 insiders) ·Filed May 21, 2026

NBIX

NEUROCRINE BIOSCIENCES INC
BEARISH
Impact 5/10
Horizonweeks Processed5mo ago
Insider cluster: 3 insiders, $40.8M total
Actionable Insight ▼ Bearish

Monitor for further insider selling in the coming weeks, especially if additional director/executive sales emerge. The post-acquisition selling pattern is not alarming by itself, but sustained selling could signal reduced confidence in near-term integration prospects.

DirectionBearish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$156.50
T+0 close · May 21, 2026 · via day close
Latest settled
−1.45%
T+60 · $154.23
Vs SPY
−4.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 22 $156.50entry
  2. T+1 · 6mo ago −0.50%α −1.08% · $155.72
  3. T+5 · 6mo ago +2.54%α +0.89% · $160.48
  4. T+20 · 5mo ago +3.27%α +3.44% · $161.62
  5. T+60 · 3mo ago −1.45%α −4.37% · $154.23

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two NBIX directors sold shares totaling ~$40.8M following the closing of the $2.9B Soleno acquisition, representing modest insider selling (0.26% of market cap). The sales coincide with option exercises and may reflect routine portfolio rebalancing rather than a negative business outlook, but the timing post-deal close warrants monitoring.

Key Financial Metrics

Direction
selling
Total Value
$40.8M
Insiders
3

Key Facts

  • Three directors sold shares: Kevin Gorman ($37.8M), Richard Pops ($2.4M), Leslie Norwalk ($0.6M) between May 12-19, 2026.
  • Total insider sales: $40.78M, representing ~0.26% of NBIX's $15.6B market cap.
  • Sales occurred shortly after the closing of the $2.9B Soleno Therapeutics acquisition on May 18, 2026.
  • All sales were accompanied by concurrent option exercises (non-cash) at lower strike prices.

Financial Impact

$40.78M in insider sales, ~0.26% of market cap

insider ownershipdilution from option exercises

Risk Factors

  • Additional insider sales may pressure the stock in the short term.
  • Integration of Soleno's VYKAT XR could face commercial or regulatory hurdles.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NBIX-1779400217159

Track record

30 reports on NBIX

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
  2. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  3. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  4. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  5. Nov 2, 202614d ago Press Release Bullish 6/10 No price data
  6. Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  7. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  8. Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
  9. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
  10. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
Showing 10 of 30

US Market Status

Market Closed · Opens in 8h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 21, 2026